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 For most of human history, breastfeeding has been the optimal source of 
nutrition for infants. Human milk contains a variety of important nutritional 
sources including vitamins, fats, proteins, and immunological components. With 
the rise of artificial infant formulas, however, breastfeeding as a whole has 
decreased around the world. Preterm infants are especially susceptible to 
diseases such as necrotizing enterocolitis in the first few weeks of life. Therefore, 
they have the most to gain from the extra immunological and nutritional support 
that is present in human milk. Within the last few decades, donor human milk has 
been viewed as the next best option if mothers own milk is not available. Donor 
human milk contains many of the same beneficial milk properties as regular 
human milk including immunoglobulins and human milk oligosaccharides. 
Studies have shown decreases in preterm cases of NEC and fewer deaths in 
infants who received DHM. One argument against the use of DHM is that 
pasteurization can reduce the beneficial enzymes and immunoglobulins present 
in samples. However, the increased use of human milk fortifiers has been able to 
significantly decrease the nutrient gap between regular human milk and donor 
milk. Overall, DHM along with proper fortification serves as the best and most 
cost effective way to feed preterm infants if mother’s milk is unavailable. 
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Throughout human history, breastfeeding has been considered the 
optimal source of nutrition for all infants. The American Academy of Pediatrics 
recommends breastfeeding for six months along with additional breastfeeding 
supplemented with compatible foods for as long as desired by the infant.1,2 
Medical opposition to breastfeeding is scarce, as human milk remains the main 
standard for infant nutrition.  Infants who have been fed human milk are less 
hospitalized in the year after hospital discharge than those who use formula. In 
addition, breast milk can reduce an infant’s likelihood to develop allergies, 
diabetes, eczema, celiac disease, inflammatory bowel disease, and childhood 
obesity. Human milk has also been shown to have positive effects on 
neurocognitive and cardiovascular outcomes in preterm infants as well.13 
Mother’s own milk is the optimal first choice for infant nutrition; however, not all 
mothers are able to breastfeed in the immediate weeks after birth. Medical 
complications such as infections and nonmedical obstacles including having to 
return to work early or poor family support can all prevent an infant from receiving 
the benefits of breast milk.4 If the mother is unable to breastfeed, human donor 
milk is the next best option. Preterm infants, especially, need the extra 
immunological and nutritional support in the first few weeks of life to ensure 
viability. This increases the need for human milk properties. Unfortunately, many 
mothers of preterm infants often have limited ability to lactate immediately upon 
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birth of the infant: the time that is most critical. Thus, preterm infants have most 
to gain by provision of breast milk from alternative sources. 
 
In the last few decades, donor milk has become an increasingly popular 
choice as either a substitute for formula or as a supplement for mother’s own milk 
if her supply is insufficient. Donor milk has been shown to help preterm infants in 
Neonatal Intensive Care Units (NICU) and has decreased the incidence of 
various infections that are common among preterm infants such as necrotizing 
enterocolitis (NEC).3 The unique, beneficial qualities of human milk are no match 
for artificial formula. Donor milk gives infants the opportunity to receive the 
immunological support that formula milk does not. These initial support systems 






The benefits of human milk are well known have been largely researched 
for many years. Donor human milk, however, is still a relatively new concept that 
has only taken effect at some NICUs around the country. Despite its infancy, 
much evidence has been gathered to show its benefits exceed those of 
traditional infant formula. However, donor milk is not currently a standard for 
preterm infants. In this thesis, I will be analyzing the known benefits of human 
milk including its immunological and developmental components, analyze current 
methods of donor milk processing, understand current concerns of donor milk 
safety and limitations, examine different methods of milk fortification, and 
investigate the long term cost effectiveness of donor milk versus formula. In 
addition, the long-term outcomes including risk of preterm diseases such as 




BENEFITS OF HUMAN MILK 
 
Composition of Human Milk 
 
Human breast milk has a general composition of 87% water, 3.8% fat, 1% 
protein, and 7% lactose.5 The composition of human milk, however, changes 
over time. The first milk secreted immediately after birth is known as the 
colostrum. It contains a significantly higher protein content than the milk in the 
following days after birth. This highlights the importance of protein especially in 
the early days of infancy. Variations in protein content changes throughout 
lactation as well as partial versus complete breast expression. The milk secreted 
in the first three months has a protein content ranging from 1.4-1.6 g/100 mL. It 
drops to 0.8–1.0 g/mL three to four months after birth and then levels out to 0.7–
0.8 g/100 mL after six months.5 Unlike protein content, lactose concentration is 
consistent after 21 days postpartum. Lactose is important for maintaining stable 
osmotic pressure in human milk and aids in the absorption of various minerals 
including calcium.  
 
Human milk contains various nutritional components that are vital for 
infant growth. These include alpha-lactalbumin, serum albumin, casein, glucose, 
lactose, and sodium. Additionally, human milk contains large quantities of 
erythropoietin, the hormone that increases red blood cell count.6 Studies have 
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also shown that erythropoietin may prevent anemia in premature infants.7 Human 
milk feeding also contributes to lower rates of obesity among children as the 
specific macronutrients present in human milk regulate the hypothalamus which 
influences appetite.8 Metabolic effects of human milk also include a decrease in 
blood pressure among adolescents and lower ratios of low-density lipoprotein 
(LDL) to high-density lipoprotein (HDL).9 A significant relationship was observed 
between human milk feeding and cholesterol profiles later on in life. 
 
Another component vital for proper infant development is 
docosahexaenoic (DHA). DHA is important for regulating growth, cognitive 
development, and motor systems in infants. About 80% of DHA in the fetus is 
obtained from the 26th week of gestation up until birth. Infants born prematurely 
miss out on this crucial transmission of DHA leading to higher rates of neonatal 
mortality.10 Thus, it is imperative that the preterm infant receives adequate 
supplementation of these fatty acids either through human milk or formula. 
Human milk also contains a variety of other factors including immunological 
components, oligosaccharides, and various growth factors and cytokines, which 




Immunological Components of Human Milk 
 
 
Perhaps some of the most important aspects of breastfeeding are the 
immunological components that are largely present in human milk but absent 
from formula. Human milk glycoproteins, lysozymes, oligosaccharides, and urea 
are just a few of the vital components that enrich the neonate. Glycoproteins 
such as α-lactalbumin, secretory immunoglobulin A (sIgA), lactoferrin, casein, 
and leptin have been shown to protect against microbial infection and excessive 
inflammatory responses in vitro. The various cells that are contained in human 
milk such as T-cells, macrophages and lymphocytes and perhaps stem cells, 
give the newborn infant a temporary immune system.6 
 
Other components of human milk can prevent infections and protect the 
gastrointestinal tract.3 Many of these effects can be attributed to human milk 
oligosaccharides (HMOs). About15 different structures of these glycans have 
been identified in human milk. Each HMO has a backbone of either glucose, 
galactose, N-ethylglucosamine, fucose, or sialic acid. Additionally, all HMOs have 
a lactose molecule at the reducing end bonded via β1, 4-glycosidic bond to a 






3 typical structures of human milk oligosaccharides 













As the third largest component of human milk, HMOs function as 
prebiotics that create and maintain proper microbiota composition by promoting 
growth of beneficial bacteria.12 Prebiotics are dietary glycans that stimulate gut 
colonization by beneficial bacteria and provide health benefits.13 HMOs are 
known to be indigestible by the human gut and pass into the distal gut where 
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they can be metabolized by the intestinal microbiota. Breastfed infants are known 
to have a prevalence of bacteria known as Bifidobacterium bifidum, which are 
integral for the acidification of the gut and colonization of other probiotic 
bacteria.12 Strains of Lactobacilli are crucial to maintaining a healthy gut 
microflora as well.13 These bacteria digest the prebiotic sugars which are then 
fermented to produce organic acids that lower the pH of cells. This suppresses 
the number of potentially hazardous bacteria in the gut, lessening the risk of 
morbidity and death in breastfed infants. Studies have shown that HMOs also 
support cooperative mutualism. Cooperation among different species of gut 
bacteria metabolize HMOs more efficiently than any single species alone.14 
 
HMOS also can indirectly increase short chain fatty acid (SCFA) 
production. B. bifidum mediates elevated levels of these SCFAs. They serve as 
an important source of energy for enterocytes and improve overall intestinal 
health. SCFAs have also been shown to have wider systemic effects by acting as 




Figure 2:  HMOs promote colonization of beneficial bacteria 
 
In this simplified schematic, blue shapes represents gut epithelial cells, 
red ovals represent hazardous gut bacteria, green ovals represent 



































This represents an almost 
equal mix of undesirable 
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the gut without the 











Here, the presence of 
HMOs has reduced the 
number of hazardous 
bacteria, as they are 
unable to digest these 
compounds. Thus, the 
beneficial bacteria have 
replicated and are now the 





Various studies have shown that in addition to the known prebiotic effects, 
HMOs may also have other mechanisms that protect the breastfed infant. HMOs 
have also been shown to have a trophic effect on intestinal mucosa and can 
directly interact with cells of the immune system.15 Most pathogenic 
microorganism virulence is attributed to the ability to adhere to the pathogen’s 
epithelial surface of the host cell through lectins (glycan-binding proteins). 
Human milk glycans inhibit pathogens from binding to intestinal mucosa by 
mimicking the structure of epithelial cell surface glycans so they function as 
competitive inhibitors.12,13,16 This allows them to serve as lectin analogs and 
block attachment giving breastfed infants a significant advantage over those who 
do not receive HMOs. For example, Campylobacter pylori is often the major 
cause of bacterial diarrhea in infants in developing countries. It is known that 
breastfed infants have lower rates of diarrhea because of HMOs inhibition of 
pathogen binding. In this case, Campylobacter binds to the H-2 epitope that is 
expressed on the surface of human intestinal epithelium. This is inhibited by the 
HMO 2’-fucosyllactose (2’FL). This suggests that HMOs are an integral 
component of an innate immune system in human milk.13 In one study, Infants 
who have tested positive for E. coli in their stools and exhibited symptoms of 
diarrhea had consumed milk with lower concentrations of these HMOs than those 
who consumed human milk with higher concentrations of HMOs. As a result, 
oligosaccharide concentration in human milk is crucial for protecting infants 
against pathogens.13  
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HMOs may also aid in the blocking of HIV-1 transmission from mother to 
infant during breastfeeding.17 Despite the fact that many infants are continuously 
exposed to HIV-1 for months during breastfeeding, most do not become infected. 
HIV-1 entry is regulated through binding of a glycoprotein (gp120) to DC-SIGN 
(dendritic cell-specific ICA3- grabbing non integrin) on human dendritic cells. 
HMOs compete with HIV glycoprotein (gp120) binding to DC-SIGN. Because 
HMOs binds to DC-SIGN, the virus is not able to enter the cells.17 In addition to 
the anti-adhesive properties, recent data indicates that HMOs have glycome 
modifying effects.16 These effects regulate the attachment sites for many 
pathogens, which serve as another protective mechanism for breastfed infants. 
 
Noroviruses (NVs) are another major cause of diarrhea in humans and in 
particular, infants. NV-binding epitopes in milk, however, inhibit the binding of the 
virus to its host. This soluble glycan competes for binding with the host cell 
surface glycan that directly inhibits the ability of the virus to attach to the host cell 
receptor, thus the cell cannot be infected. Norovirus diarrhea occurs less 
frequently in infants whose mother’s milk contained high levels of lacto-N-
difucohexaose (LDFH-I).12 This is a 2-linked fucosyloligosaccharide, which has 




Figure 3: HMOs prevent pathogen binding to host cells 
 
Blue shapes represent gut epithelial cells, purple shapes represent 





































3B: HMOs compete for binding with host surface receptors preventing pathogens 
from binding with the host cell. 
 
  














Rotavirus infections are also responsible for many of the infant diarrhea 
cases around the world, especially in developed countries. It has been shown 
that the rotavirus ability to infect MA-104 cells in culture can be inhibited by 
lactadherin, a glycoprotein found in human milk. The inhibition is dose dependent 
and relies on the removal of sialic acid from the compound suggesting the glycan 
part of the protein is responsible for the inhibition.12 The protection against 
rotaviruses during nursing is essential as it is when the infant is most vulnerable. 
The infant can then develop its own antibodies for future protection. 
 
Anti-Inflammatory Effects of Human Milk 
 
Many crucial anti-inflammatory agents have also been identified in human 
milk. These include anti-proteases, lysozyme, lactoferrin, secretory IgA, and 
antioxidants, including ascorbate, cysteine, alpha-tocopherol, and beta-
carotene.18 Additionally, an immature intestinal mucosa often has a heightened 
inflammatory response, which may be responsible for high incidents of NEC 
among preterm infants. Human milk contains various anti-inflammatory cytokines 
including IL-10 that serve to diminish this response.19 HMOs, also lacking in 
formula, can directly attenuate certain forms of inflammation. Infant formula does 
not provide adequate amounts of most of these components, leaving formula-fed 
infants without valuable temporary protection against many common disorders 
and inflammatory effects. 
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Allergy risk in breast milk fed infants is also considerably lower. This can 
be attributed to the early immunity that infants develop due to the compounds in 
human milk. For example, the neonatal immune system lacks IgA producing B 
cells. Secretory IgA (sIgA) is present in human milk. Tight junctions are not fully 
developed in infants at the time of birth, therefore many large proteins such as 
sIgA can be passed on to the infant giving it a temporary protection while the 
infant’s immune system differentiates and creates its own B-cells.19 When sIgA 
binds to a pathogen, the pathogen is rendered less infective.20 Animal models 
suggest allergen exposure through human milk helps develop regulatory T cells 
which protect the animal from asthma when encountered with the allergen later in 
life.2 
 
Other components of Human Milk 
 
 
While HMOs and immunoglobulins are perhaps the most well known 
components of human milk, they are certainly not the only ones of importance. 
Mucins, glycosaminoglycans (GAGs), and glycolipids all confer large advantages 
to the neonate. Mucins are high molecular weight hydrophobic glycoproteins 
found in human milk that are involved in a range of functions. Similar to HMOs, 
mucins play a role in inhibiting the ability of a pathogen to bind to a host cell.21  
 
Glycosaminoglycans belong to a class of anionic polysaccharides 
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responsible for maintaining the extracellular matrix and play a role in the 
lubrication of joints. However, they are also found in human milk. Preterm milk 
has about 3 times the amount of GAGs as term milk highlighting the importance 
of their function. Like HMOs, GAGs play a protective role in the developing 
neonate. For example, they have been shown to also inhibit the binding of gp120 
to the CD4 receptor preventing HIV infections.13 
 
Lastly, glycolipids or more specifically glycosphinogolipids make up a 
portion of the lipids found in the human milk fat globule membrane. Gangliosides, 
a type of glycosphingolipid, contain a sialic acid moiety also found in other HMOs 
and share similar properties. For example, the GM1 ganglioside can bind to 
cholera toxin, labile toxin of E. coli and a toxin from Campylobacter jejuni, thus 
protecting the infant against dangerous diarrhea.13 
 
 
Human milk and NEC 
 
Necrotizing enterocolitis (NEC) is one of the leading causes of death for 
preterm infants.8 More than 10% of all low birth weight infants develop NEC and 
the mortality rate ranges from 10-50% depending on the severity of the 
disease.16 The initial disruption leading to NEC includes perinatal hypoxia or 
postnatal infection. These can later cause mucosal damage and impaired 
intestinal epithelial function. A number of factors have been linked to NEC 
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including prematurity, bacterial infections, hypoxia, and even formula feeding. 
Feeding infants with formula results in an increase of bacteria and 
lipopolysaccharides that lead to a heightened inflammatory response further 
damaging the intestines.16  
 
Figure 4: Flow diagram of NEC pathogenesis and benefits of HMOs 




















Studies have noted a significant decrease in rates of NEC in preterm 
infants who were fed human milk rather than formula milk.12,16 Formula-fed 
infants have reported to have a NEC incidence rate of 6-fold higher than that of 
human milk fed infants. Formula-fed infants are at a higher risk for NEC because 
they lack beneficial components that are only found in breast milk. These include 
the platelet-activating factor (PAF) degrading enzyme PAF acetylhydrolase (PAF-
AH) and long chain polyunsaturated fatty acids (LC-PUFA). PAF binds to a G-
protein coupled receptor that initiates signaling resulting in epithelial apoptosis 
and an increased inflammatory response- key events in NEC. Infants with NEC 
have high serum levels of PAF and low levels of the PAF-AH indicating PAF-AH 
plays a protective role in prevention of NEC.22 Preterm infants, especially have 
endogenous PAF-AH deficiency, which places them at an increased risk for the 
disease.  Additionally, LC-PUFA has been shown to modulate inflammation 
through cytokines and T-cells. Supplementation with LC-PUFA in infancy can 
also down regulate the inflammatory response and help prevent future allergies 
and other immune related diseases.23 
 
Key events in NEC pathogenesis such as neutrophil infiltration and 
reactive oxygen species (ROS) production have been reduced by HMOs.16 
Additionally, consumption of human milk results in decreases in overall morbidity, 
nosocomial infections, urinary tract infections, retinopathy of prematurity, 
gastroesophageal reflux disease, diarrhea, insulin resistance, feeding 
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intolerance, and bronchopulmonary dysplasia.12 Gastric motility is also enhanced 
in infants fed human milk. 
 
Developmental Components of Human Milk 
 
Cognitive development remains crucial to infant and child growth. 
Impaired cognition from a young age due to various neonatal factors can 
contribute to the poverty and difficulty later on in life. There are various 
developmental components that have been shown to benefit children and adults 
who have been breastfed as opposed to formula fed. Human milk contains high 
concentrations of important brain development compounds. These include 
choline, sialic acid, and LC-PUFA. Prenatal exposure to choline has shown 
greater hippocampal development, learning, emotional behavior, and learning.2,18 
Greater breast milk intake was also associated with better corpus callosum 
maturation at 40 weeks.24 Additionally, studies have suggested that breast milk 
fed infants and mixed fed infants (formula and HM) have more labile 
temperaments and lower impulsivity ratings than formula fed infants.25 
 
The cognitive benefits of human milk also extend beyond the prenatal 
years. In a cohort study of 180 preterm infants, a favorable association was 
found between the intake of human milk in the first 28 days with 
neurodevelopmental outcomes at 7 years of age. For each additional day that 
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breast milk intake was over 50% of total enteral intake, IQ was measured to be 
0.5 points higher.26 While previous studies also support a positive relationship 
between human milk and cognitive outcomes, most of them were examined in 
toddler outcomes, which are less predictive of later abilities. This study reinforces 
the long-term effects of human milk. 
 
Other compounds that effect neonatal development include 
docosohexaenoic acid and arachidonic acid. These enhance brain growth and 
visual development. Epidermal growth factor (EGF), insulin-like growth factor-1 
(IGF-1), transforming growth factor (TGF- β), and lactose are also present in 
human milk in high concentrations. These growth factors are imperative for 






Introduction to Formula 
 
Breastfeeding is often contraindicated for a variety of reasons. Mothers 
with infections such as HIV, tuberculosis, or chickenpox can often transmit the 
infection to their newborn. Additionally, some infants are unable to breastfeed 
due to various birth defects including cleft palate that do not allow the baby to 
create adequate suction to obtain the milk. Lastly, the mother’s personal beliefs 
and preferences can also be taken into account. Breastfeeding can often be 
tiresome and a burden at times. Some mothers would prefer to try other methods 
of feeding due to busy schedules. Among new mothers in the US, only about 
43% breastfeed for any portion of time and only 13% breastfeed exclusively for 
six months. Formula is often an appealing choice for mothers who, for a variety 
of reasons, are unable or unwilling to breastfeed. 
 
  Infant formula is available in three forms- powder (the cheapest option), 
concentrated liquid, and ready to feed liquid (the most expensive). The 
composition of formula is highly regulated and all manufactures must adhere to 
the guidelines set by the government. This includes meeting the minimum and 
maximum ranges for each nutrient, avoiding fructose due to fructose intolerance, 
and only introducing L forms of amino acids to avoid D-lactic acidosis.5 
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 Formula is also classified into three major classes. Cow based formula, 
soy-based formula, and specialized formulas which all vary to meet a wide range 
of needs. Cow milk is the most widely used base for most formulas. However, it 
must be diluted to match human milk as cow milk contains higher levels of fat, 
minerals, and protein, which infants cannot take. Infants that are allergic to cow 
milk are unable to tolerate this type of formula and required a substitute. Soy-
based formulas are made from soy proteins and are good options for infants with 
congenital lactase deficiency or galactosemia (US National Library of Medicine, 
Infant Formulas). Other specialized formulas include amino acid formulas and 
hypoallergenic formulas for infants with specific needs. 
 
Infants that are fed with formula, however, tend to have a microflora that is 
similar that of adults. Infants are not supposed to have a complex digestive 
system so soon after birth.1,5 Beneficial bacteria such as Bifidobacterium bifidum 
that are supposed to colonize the infant gut require the presence of HMOs to 
thrive.  
 
Formula Milk improvements 
 
In the last few years, formula milk has improved tremendously because of 
enhanced supplements, including PAF-AH and LC-PUFA. Supplemented infant 
formula with PAF-AH and LC-PUFA has been shown to reduce NEC incidence in 
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animal models, however, these improvements do not make up for the even 
higher decrease of NEC in DHM fed infants. Additionally, human milk still 
remains more beneficial because of the few oligosaccharide functions that 
cannot be replicated in artificial infant formula.16  
 
Many complex are found only in human breast milk and are hard to 
replicate synthetically.27 This poses as a challenge for formula manufacturers 
who aim to compete with DHM. At first, researchers believed that bovine milk 
may hold the key to finding similar oligosaccharides that formula may lack. These 
bovine milk oligosaccharides (BMOs), however, are found in much lower 
concentrations than HMOs making it historically difficult to analyze their 
characteristics. Recently, 40 different BMO structures have been identified that 
are analogous to HMOs.28 This suggests that BMOs have a similar protective 
role in the cow gut. 
 
Various formula producing companies are trying to find alternatives to 
HMOs. Current replacements on the market include galactooligosaccharides 
(GOS), fructooligosaccharides (FOS), inulin, and pectin. These resemble the 
effects of HMOs and create attempt to create microbiota that is closer to those of 
breast fed infants but with some key differences. The proper function of HMOs 
relies heavily on the specific structure of the oligosaccharides. Therefore, 
oligosaccharides such as FOS and GOS that differ in structure from HMOs may 
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have different effects on the neonate. For example, HMOs are sialyated, while 
GOS and FOS are not. They do not contain the negatively charged carboxyl 
group that is vital for certain HMOs effects.27 GOS consists of 1-7 galactose 
moieties with a glucose at the non-reducing end while FOS is a b1-2 fructose 
polymer (Figure 5).16,28 Overall, FOS and GOS are also much simpler structures 
than naturally occurring HMOs. 
 
Figure 5: Structural comparison of GOS, Inulin, HMO, and BMO  









While BMOs and other synthetic or naturally occurring oligosaccharides 
are promising, they fail to provide the same protective effects of HMOs in the 
infant. A study compared gastrointestinal epithelial transfer and immuno-
modulary properties of HMOs, BMOs, and pectin. While all of the structures were 
transported across the epithelial cells, only HMOs were able to modulate 
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postnatal allergen-specific immunosuppression in atopy-prone individuals.29 This 
reinforces the idea that the specific structure of HMOs is vital for protection for 
the neonate and attempts to replace them cannot mimic their specific effects. 
Despite large improvements, the gap between formula milk and human milk 




DONOR HUMAN MILK 
 
Donor Human Milk Processing 
 
As of November 2019, there are 29 milk banks spread across the North 
America that process, collect, store, and distribute DHM to hospitals across the 
continent (Human Milk Bank Association of North America- HMBANA). A 
potential donor must pass a series of tests including a telephone interview. The 
mother must be lactating and have a surplus of milk in order to donate. She 
cannot smoke, drink alcohol within a certain time frame, or regularly use 
medications including megavitamins. Laboratory testing for HIV, Hepatitis B and 
C, syphilis, Human T-lymphotropic virus is also required, with all expenses paid 
by the milk banks. A mother cannot donate if results from laboratory testing are 
positive, she has stayed in the UK for more than three months, or has traveled to 
Cameroon, Central African Republic, Chad, Congo, Equatorial Guinea, Gabon, 
Niger, or Nigeria.  
 
Once the milk has been collected, samples from different donors are 
pooled, poured into appropriate containers, and pasteurized using Holder 
pasteurization conditions.1 Pasteurization occurs for 30 minutes at 62.5°C.30 This 
technique removes all bacteria, including pathogens that may have contaminated 
the milk. The pasteurized donor milk is screened for any microbial contaminants 
before it is delivered to NICUs and other infants in need throughout North 
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America. At the moment, over 65% of NICUs across the United States use DHM 
in regular practice.31 
 
Figure 6:  Processing of human donor milk at a milk bank 


















Donor Human Milk and Preterm Infants 
 
Approximately 12% of all infants born in the US are premature. Preterm 
infants are at a much greater risk for developing neonatal problems like NEC and 
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feeding intolerance due to the immaturity of their gastrointestinal system. 
Necrotizing enterocolitis is characterized by acute inflammation in the intestines 
of preterm infants. Multiple studies comparing the use of DHM to formula have 
shown a reduction in the incidence of NEC, sepsis, and broncopulmonary 
dysplasia in DHM fed infants. Additionally, DHM provides enhanced feeding 
tolerance and prevention of hypertension, and insulin resistance.32 
 
Although human milk is the standard for infant nutrition, for preterm 
infants, it alone does not provide ideal nutrition. This evidence enforces the idea 
that human milk should be fortified for proper growth. There are complications, 
however. Many commercial milk fortifiers have been marked with increases in 
metabolic acidosis and markers of oxidated stress.33 Because of this, significant 
research has gone into creating fortifiers made from human milk or human donor 
milk. While donor milk has a significant positive influence on full term infants, its 
effects on preterm infants are even more crucial. Meta-analyses of 4 randomized 
clinical trials confirm that feeding infants human milk results in higher IQ, more 
white matter, and greater total brain volume. Additionally, human milk feeding 
has resulted in lower rates of severe retinopathy of prematurity. Feeding 





CONCERNS FOR DONOR MILK LIMITATIONS 
 
DHM and Pasteurization 
 
 
The evidence for donor milk is overwhelmingly positive. On the other 
hand, there are certain concerns regarding the overall effectiveness of donor milk 
versus other methods of infant nutrition such as formula milk. Pasteurization 
remains a crucial step in the processing of DHM. Because a high amount of heat 
is used to eliminate the bacterial and viral pathogens, it is inevitable that certain 
proteins and beneficial components to the milk are destroyed. These include B 
and T lymphocytes, IgA, lactoferrin, lysozyme, alkaline phosphate, cytokines, 
lipases, water-soluble vitamins, and various other proteins and growth 
factors.35,36 IgA is crucial for preventing microbe infiltration into the body’s 
tissues. The lack of IgA after pasteurization is a problem that researchers are 
currently attempting to resolve, although some studies have reported minimal IgA 
destruction.37 In addition, the repeated freeze-thaw cycles that inevitably 
transpire with donor milk can heighten these damaging effects.38 Overall fat and 
energy content after pasteurization is also decreased.  
 
Many of the cytokines present in human milk are believed to play a role in 
developing the human intestine. Thus, a decrease in these factors could 
adversely affect an infant’s immature gut. A study by Giorgi et al. compared 
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concentrations of different anti-inflammatory cytokines before and after Holder 
pasteurization of DHM. A portion of the results is seen in Figure 7. 
 
Figure 7: Percentage of cytokines preserved after pasteurization 
















IL-8 was the only cytokine that was almost completely conserved after 
pasteurization at 89%. It is believed that due to its strong tertiary structure, IL-8 
may be less susceptible to heat disintegration. IL-2 and IL12p70 also share 




Another study quantified ganglioside concentrations after pasteurization at 
different temperatures. As previously stated, gangliosides make up the majority 
of glycosphingolipids found in human milk and confer an immunoprotective 
advantage to neonates. Results showed that ganglioside content at 63°C/30 min 
and 72°C/15s had no significant structural variations. Ganglioside concentration 
also remained stable up for up to 90 days when refrigerated or stored at room 
temperature.40 Despite the reduction in some biologically active components, a 
majority of the beneficial ingredients in human milk including HMOs, LC-PUFA, 
gangliosides vitamins A, D, E, and lactose still function. Pasteurized donor milk 
still has more nutritional, immunological, and developmental benefits when 
compared with formula milk. 
Recently, a new type of pasteurization known as Short Time High 
Temperature (STHT) processing has been shown to reduce the loss of many 
important milk factors. STHT pasteurizes milk for 5-15 seconds at 72°C. In a 
study comparing the effects of Holder pasteurization and STHT on 
cytomegalovirus transmission, STHT was able to preserve 10% of lipase activity 
and 57% of AP marker enzyme activity whereas Holder pasteurization destroyed 
nearly all enzyme activity.41 Additionally ultraviolet irradiation (UV-C) has also 
been researched as an alternative to heating samples. UV-C pasteurized human 
milk irradiated with a dosage of 4683 J/I was shown to have higher retention 
rates of immunological proteins than milk treated by Holder pasteurization. These 
proteins included sIgA, lysozyme, and lactoferrin. Both STHT and UV-C 
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pasteurization are still relatively new techniques, however. More research needs 
to be done to determine safety and efficacy prior to widespread implementation. 
 
In addition to pasteurization concerns, donor milk has some other 
limitations. Many preterm and very low birth weight infants (VLBW) require more 
nutrients than full term infants. Donor milk does lack a few vital components, 
which may inhibit the VLBW infant to grow and develop properly. Most mothers 
who donate milk have already fed their own infants and are pumping for donation 
later in lactation. The later a mother lactates, the less protein, fat, and bioactive 
molecules will be present as compared to milk that is pumped preterm or early on 
in lactation. This may inhibit the infant from obtaining all the nutrients he/she 
needs. Additionally, most mothers who donate milk have given birth to term 
infants; thus reinforcing the idea that donor milk may not meet the nutritional 
requirements for preterm or VLBW infants. Preterm donor milk has a higher 
amount of nutrients but is rare and often used for these extremely vital cases.  
 
DHM and Growth 
 
While human milk does provide the optimal source of nutrition for infants, 
it alone does not meet the needs of all premature neonates. One of the biggest 
challenges in providing human milk to preterm infants is the lack of infant growth. 
Many preterm infants who are fed human milk without supplements do not grow 
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at the intrauterine rate.34 Additionally, preterm infants are not as tolerant of high 
fluid volumes as term infants, whereas human milk was selected, by evolution, to 
feed the term infant.35 A majority of fetal growth happens in the third trimester, 
thus preterm infants have not achieved full growth by the time they’re ready to 
feed. It is crucial that low birth weight and VLBW infants receive the proper 
amounts of nutrients to avoid complications later in life. Additionally, their organ 
and immune systems are not developed and the amount of nutrients that are 
stored is substantially lower than that of full term infants.  
 
The lack of protein in donor milk supports lower rates of weight gain and 
overall growth (linear and head) versus that of infants who received formula. In a 
study that compared a DHM diet to a formula diet, postnatal weight gain, growth 
in head circumference, and gains in triceps and subscapular skinfold thickness 
were all significantly lower in DHM fed infants than the infants fed with formula.37 
Long term growth at 9 months, 18 months, and 7.5–8 years was also measured 
in one study. Formula fed infants had a higher body mass index at 18 months, 
but other than that time point, there were no differences in the long-term effects 




Researchers, however, are still debating the significance of this initial lag 
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in growth, as the early periods in neonatal growth are critical to the developing 
brain. Lacking proper nutritional content can hamper cognitive development.  In a 
study by O’Connor, VLBW infants fed fortified human milk showed superior motor 
and developmental outcomes despite the initial lag in growth.42 While this study 
was promising, more research needs to be done to fully understand the 
implications of delayed growth. To combat the initial lag in growth for DHM fed 
infants, individual donor milk fortification may be effective in improving what 
unfortified donor milk is lacking. While protein is the main component missing 
from donor milk, insufficient intake of other nutrients including calcium, 
phosphorus, zinc, copper, selenium, and iron can lead to other deficiency 
diseases including osteopenia.  
 
Standard (STD) donor milk fortification is the most commonly used 
method of milk fortification which entails adding a fixed amount of nutrients to 
meet recommended nutrient intakes.43 It has been implemented with some 
success; however, the overall protein content is still lower than what VLBW 
infants need. STD fortification still fails to provide adequate protein amounts. In 
order for postnatal growth to match the rate of intrauterine growth, protein intake 
must equal about 15 g/kg/day. STD fortification only provides an average of 2.5-
2.9 g/kg/day.44 Additionally, the protein content of mother’s milk changes 
throughout the entirety of lactation. There is always a level of concern that too 
much protein will be added to donor milk, as the current protein content of donor 
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milk is usually estimated. Excessive amounts of protein can also be dangerous 
for the developing infant, however, it is rare that these assumed protein content 
estimates even reach those levels. With this variation in mind, there has been a 
call for the individualization of HM fortification.  
 
Since no two preterm infants or samples of donor milk are exactly alike, 
HM fortification should also be modified to each infant’s nutritional and dietary 
needs. The two current individualized types of fortification are known as targeted 
fortification and adjustable fortification.15,44 Targeted fortification consists of 
analyzing DM periodically and adjusting protein/nutrition intake according to 
various predetermined requirements of preterm infants. In a study conducted by 
Rochow et al. milk analysis was conducted twice daily. Fat, carbohydrate, and 
protein content were added based off of the ilk analyses and given to infants. The 
growth rates of the infants with targeted fortification were not much different the 
growth of the infants given STD fortification. However, there was a high 
correlation between the volume of milk given and the weight gain in the targeted 
fortification group, which was not seen in the STD group.45 Additionally, targeted 
fortification requires a milk analyzer, which can be quite expensive since this 
technology was originally developed for the dairy industry.43  
 
Adjustable fortification differs as it depends more on the infant’s metabolic 
response. Blood urea nitrogen content (BUN) is periodically determined and DM 
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fortification is adjusted based off of these findings. The benefits of adjustable 
fortification include the avoidance of excessive protein intake and there is less of 
a need for frequent milk analysis. This type of fortification is well suited for 
nurseries that are not suited for frequent labor intensive analysis.44 In two 
observational studies, adjustable fortification was associated with improved 
growth and neurodevelopmental outcomes. Ergenekon et al. reported gains in 
both head growth and weight in preterm infants.46 Biasini et al. also showed this 
high protein intake was associated with improvements in mental development 
scores at 12 and 24 months of age.47 Although formula fed infants historically 
have higher rates of short-term growth, the benefits of human milk and new 







How it works Advantages  Disadvantages 
Standard (STD) - A fixed amount 
of fortifier is 
added to a fixed 









intake for VLBW 
infants 
- VLBW still 
continue to report 
suboptimal growth 








- Can provide 
sufficient amount of 
macronutrients 
according to exact 
measurements of 
DHM 
- Can be labor 
intensive 
- Supplementation 
is based on 
standard 
recommendations 
and not on each 
infant’s individual 
needs 
Adjustable - Protein 
concentration is 
measured by 
each infant’s BUN 
twice a week 
 
- Monitors the protein 
intake of each 
individual infant 
- Is a more 
customizable way to 
fortify DHM 
- Does not require 
expensive devices 
- Safeguards against 
extra protein intake 
- Requires 
frequent 
monitoring of each 
individual infant 
 




DHM and NEC 
 
As previously stated, NEC is a costly and deadly disease that affects 
many preterm and VLBW infants around the world. The costs of treating NEC in 
infants are so large that any potential preventative measures should be taken 
into account. Research has proven that preterm infants who receive donor 
human milk are significantly less likely to develop NEC than those who receive 
formula or bovine fortified milk diets.48,49 The excessive protein intake that is 
attributed to formula feeding and fast growth compared to that of human milk has 
been linked to unfavorable markers of cardiovascular risk and NEC in infants.50 
While HM fortification with human milk fortifiers is ideal, supplementation with 
bovine fortifiers is often cheaper and was the choice of physicians for many 
years. A study by Schanler et al. found no significant effect of donor milk on 
NEC; however, the donor milk in the study was fortified with bovine-based 
fortifiers and not human fortifiers as discussed in the previous section. By 
increasing risk of their use, these bovine fortifiers may have masked other 
putative benefits of donor milk.48 A study by Sullivan et al. compared bovine 
fortifiers to the human fortifier Prolac+H2MFTM.48 The group that received the milk 
supplemented with human fortifier showed a decreased incidence of NEC. This 
suggests that there can be negative effects of bovine milk products on the 




Meta-analysis of the clinical effects of donor milk to formula found that 
when unfortified DHM was the only source of nutrition, the risk of NEC dropped 
by approximately 79%. 37 This speaks to the importance of the benefits of DHM 
despite the negative effects that pasteurization may have on donor milk. One 
could insinuate that fortified DHM would have had an even lower NEC risk. The 
review also found that there was a significant difference in the number of feeding 
intolerance cases (NEC and diarrhea) when the infants were fed donor milk 
rather than formula. Another meta-analysis by Quigley et al. showed NEC rates 
of 70/1000 infants for formula fed infants versus 37/1000 for DHM (unfortified and 




COST EFFECTIVENESS OF DHM  
 
 
Although many NICUs across the continent use donor milk, it is not 
currently the widespread standard for mothers who cannot breastfeed their 
children. Most NICUs turn to formula milk as a substitute for breast milk as 
formula is cheaper and more appealing compared to the higher initial costs that 
are associated with DHM. Overall, DHM is not as common as formula, therefore, 
its prices are naturally higher. According to the Milk Banking Association of 
America, the average price of DHM is $4.50/oz. The average amount for preterm 
milk is slightly higher at $5.00/oz.  The higher price for preterm milk is due to the 
fact that it is usually in shorter supply than term milk and used for extremely 
preterm or VLBW infants who need the extra nutritional and immunological 
support.  
 
NEC, obesity, and other common diseases among both preterm and full-
term infants contribute to the higher costs of neonatal care. However, if one uses 
formula milk as the main source of nutrition, the incidence of NEC and other 
neonatal diseases increase, thus the overall price of nutrition and care increase 
as well. If donor milk is used from the beginning, the odds of complications 
arising decrease and the overall price for infant nutrition and care may ultimately 




To compare the prices of donor milk to breast milk, Edwards et al. 
calculated the overall costs attributed to donor milk and total parenteral nutrition 
(TPN) per infant at the Children’s Hospital of Philadelphia (CHOP). CHOP spent 
approximately $426 per day on donor human milk or $47 per patient. This is 
higher than the average cost of total parenteral nutrition used for at risk preterm 
infants ($1436.46 per patient daily). This results in $18.4 million spent on TPN 
per year at CHOP. When compared with the cost of donor milk, Edwards found 
that $8800 per infant can be saved.  
 
Ganapathy et al. performed a similar study and showed the average 
length for hospital care for NEC infants was 64.5 days with a cost of $207,378 in 
2011. The average length of stay and cost of an extremely premature infant 
without NEC care is 11.7 days with a total cost of $74,004. The length of an 
extremely premature infant stay with surgical NEC is 43.1 days with a total cost 
of 198,040.51 Additionally, if there is a 55% decrease in the cases of NEC 
annually, about 2,438–3,548 cases could be avoided each year. This could result 
in savings of $212 million in hospitalization costs alone.51 Total economic value 
by NEC reduction and mortality costs would be $1.6–2.5 billion. The study also 
found that there is a direct net savings of $8,167 per infant when the diet is 
exclusively human milk based due to the decreased rates of NEC and the costs 
associated with longer NICU stays (Table 2). Often, circulatory and respiratory is 




























Estimation of Expected NICU Costs Among Extremely Premature Infants Fed with Bovine Milk Based Human Milk 
Fortifier versus 100% Milk Diets 
Table taken from Ganapathy et al. 2012 
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than the reality because the study did not take into account post treatment care 
costs such as additional surgeries and doctor follow-ups. Intestinal failure, a 
common post NEC complication often results in intestinal transplantation, which 
has an estimated cost range of $130,000 to $250,000. 
 
The cost effectiveness of human based milk products was also compared 
to that of bovine and preterm formula.51 The price of human milk based fortifier 
(Prolac+H2MFTM) is $6.25/mL while the price of donor milk (20 calories per oz.) 
was $3.00/oz. Bovine HMF gave an average price of $1.30 per packet, and 
preterm formula (Enfamil Premature 20 calories per oz.) was $1.00 per oz. or 
$0.03 per mL. While the lower cost of bovine fortifiers is appealing, research 
shows that there may be factors in bovine milk that negatively affect the preterm 
intestinal system. Preterm infants that were given HMF supplementation had 
significantly lower incidence of NEC compared to the group that received bovine 
supplementation.51 
 
A similar systemic review by Buckle et al. showed that the length of stay 
due to medical NEC cases added 18 days and surgical NEC added 50 days 
compared to the norm for an infant without NEC.53 Additionally, seven other 
studies showed the average cost of DHM for a VLBW infant is about $300 or 
$1500 for an infant with a birth weight of 500-1240 g.53 Although these studies 
calculated the savings of donor human milk differently, they all prove that there is 
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an overall net difference in the savings when donor milk is used over traditional 
infant formula. There is potential net savings on hospital care and treatment by 







Infant milk is more than a source of food. It supports growth, development, 
and maturation of the nervous and immunological systems. Therefore, infant 
feeding should be treated as a health issue and not a lifestyle choice. Human 
milk directly from the mother is the best source of nutrition for all infants. It has 
been, after all, evolutionarily selected to provide most of a newborn’s needs. Not 
only does HM have an almost perfect ratio of nutrients including vitamins, 
proteins, lipids, but it also provides extra protection to neonates. The 
immunological components of HM including IgA give the infant a temporary 
immune system for weeks after birth. Additionally, HMOs provide an advantage 
against pathogens that has yet to be replicated artificially. Whether it is blocking 
HIV transmission, preventing diarrhea, or reducing the risk of allergy and hyper 
inflammatory states in infants, HMOs are a vital component to the start of a 
healthy life. 
 
 Infant formula has come along way in terms of nutritional and 
developmental value over the last few decades. Additional supplementation of 
LC-PUFA, PAF-AH, BMOs, and synthetically produced oligosaccharides has 
certainly improved infant health over the last few decades. While formula is a big 
improvement over traditional methods of nutrition such as pure bovine milk, it has 
yet to match that of human milk with regard to protection and development of the 
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infant. The complexity of human milk is not entirely understood even today, 
therefore, its superiority and biological activity is hard to mimic. The effects of 
HMOs, GAGs, immunoglobulins, and other biologically active compounds are 
unparalleled in the protection of the infant.  
 
If a mother is unable to breastfeed, DHM is the next best option. While 
infant formula is convenient and tempting, it is no match for human milk. Its 
biological activity mirrors that of mother’s own milk despite the lack of a few 
bioactive compounds. What does remain, however, has proved to be significant 
over the course of various studies comparing donor milk to formula milk. 
Especially in preterm infants, donor milk is essential to providing the most 
nutritional support possible to avoid common infections such as NEC. With the 
development of new technologies including STHT pasteurization and other 
purification methods, researchers are beginning to preserve some of the 
components lost thus adding to the effectiveness of DHM. 
 
Donor milk should be used in combination with human milk fortification to 
feed preterm infants for maximum growth and development. While bovine 
fortification has been shown to lead to negative neonatal outcomes, human 
fortification is quickly progressing to become the norm. At the moment, 
adjustable fortification has the most potential for widespread implementation 
given its cheap costs and ability to meet each infant’s specific needs. The results 
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from various studies previously discussed show significant progress in areas 
such as growth where prior unfortified DHM was lacking. 
 
The investment in donor milk may seem costly. Pasteurization, collection 
of milk, and human milk fortification can make the price of donor milk a lot less 
desirable than formula. However, when taking into account all the expenses that 
are associated with increased rates of neonatal morbidity, including lengthened 
hospital stays, treatments, surgeries, and provider fees, the initial cost is merited. 
Formula while it is a convenient choice, it is not always the healthiest choice. 
Preventative care is especially important for the health and safety of our most 
vulnerable population, preterm infants, and steps need to be taken to ensure 
their viability. 
 
There is still work to be done in making sure donor human milk is 
widespread across the nation. Educating mothers on their options for infant 
feeding after birth is especially important, as many do not know that donor milk is 
available. In addition, more research is needed to analyze different cultural, 
religious, and social attitudes regarding donor milk. Despite this room for growth, 
the future for neonatal care remains bright. With new technologies improving 
pasteurization and milk fortification, the benefits and use of donor human milk are 
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